Metformin is the biggest winner in the new guidelines for diabetes prevention and treatment

On November 22, 2017, the 21st National Academic Conference of diabetes branch of Chinese Medical Association (http://www.chemdrug.com/exhibit/) was held in Chongqing Yuelai International Convention and Exhibition Center (http://www.chemdrug.com/exhibit/) The conference was hosted by Chinese Medical Association and diabetes branch of Chinese Medical Association and organized by Chongqing Medical Association The conference (http://www.chemdrug.com/exhibit/) attracted nearly 8000 diabetes workers from all over the country to participate in the academic feast, which was closely focused on The theme of "collaborative innovation and integrated development" is to give prominence to the characteristics of combination of basic and clinical research, equal emphasis on breadth and depth, equal emphasis on communication and training, and merger of academic and public interest, so as to make in-depth exchanges and discussions on the progress of basic and clinical research in various fields of diabetes New guidelines for prevention and treatment of diabetes highlight the important role of metformin On the morning of November 25, 2017, at the general meeting of the 21st National Academic Conference (cds2017) of the diabetes branch of the Chinese Medical Association, Professor Jia Weiping, chairman of the diabetes branch of the Chinese Medical Association and the Sixth Affiliated Hospital of Shanghai Jiaotong University, introduced the revision of the guidelines for the prevention and treatment of type 2 diabetes in China (2017 version) prepared by CDs to all the participants Condition It is reported that the guide will be officially published in January 2018 Figure 1: Professor Jia Weiping introduces the revision of the new version of the guidelines There are four significant changes in the new version of the guidelines First, one of the important changes in the new version of the guidelines is the update of the path map of clinical hypoglycemic treatment with guiding principles The previous first-line, second-line, third-line and fourth-line drugs (http://www.chemdrug.com/) were changed to single drug, double drug, triple drug and multiple insulin injections Fig 2: the new version of the guidelines for hypoglycemic treatment path map Second, in oral hypoglycemic drugs, metformin is still the first choice of hypoglycemic drugs Figure 3: experts agree that metformin is the first choice for strong and safe hypoglycemic Metformin can form a two-way and three-way scheme with 1-2 hypoglycemic drugs with different mechanisms of action (insulin secretion promoting agents, α glucosidase inhibitors, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, sodium glucose cotransporter 2 inhibitors) Fourth, in the comprehensive control goal of type 2 diabetes, the target value of blood pressure decreased from 140 / 90 mmHg in the 2013 guidelines to 130 / 80 mmHg There are three main points for the change of the guideline's hypoglycemic pathway: 1 The importance of metformin is highlighted; 2 In the two-way plan, the oral hypoglycemic drugs and injection drugs are separated to facilitate the grass-roots level; 3 After the treatment effect of an oral drug is poor, injection drugs can be started, including insulin and GLP-1 receptor agonists The first antidiabetic drug "dulonin" - the world's first metformin sustained-release tablet (II) was successfully launched It is reported that on the afternoon of November 23, 2017, Professor Li Qifu, member of the Standing Committee of diabetes branch of Chinese Medical Association, director of Chongqing diabetes center, director of Chongqing diabetes special committee and director of the Department of endocrinology of the First Affiliated Hospital of Chongqing Medical University, introduced in detail the effectiveness and safety of metformin hydrochloride sustained release tablets (II) in the treatment of diabetic patients Central, randomized, open, parallel controlled trial (http://www.chemdrug.com/sell/24/) "Interim research progress The results showed that metformin hydrochloride sustained-release tablets (II) were equivalent to imported metformin in clinical hypoglycemic effect, and the drug had fewer gastrointestinal side effects and better tolerance Domestic metformin surpassed the imported drugs in one fell swoop, won the unanimous praise of experts attending the meeting, and represented the latest scientific research achievements of China's diabetes medicine (http://www.chemdrug.com/) The meeting was presided over by Guo Lixin, a famous diabetes expert in China, vice chairman of diabetes branch of Chinese Medical Association, deputy leader of Endocrinology group of geriatric medical branch of Chinese Medical Association, and Professor Guo pointed out the product (http://www.chemdrug.com/invest/) It has solved the worldwide problem of poor tolerance of metformin, and provided a new idea and scheme for our clinical doctors to control diabetes smoothly and improve compliance This product is also the only sustained-release metformin tablet (II) approved by CFDA (http://www.chemdrug.com/article/11/) It is reported that under the chairmanship of Professor Guo Lixin, an expert group including Professor Liu Guoen, member of the national medical reform expert consultation committee of the State Council (http://www.chemdrug.com/) led another clinical value evaluation trial focusing on metformin hydrochloride sustained-release tablets (II) The project is a multi center clinical study involving more than 30 hospitals in China, including Beijing hospital, China Health Economics Research Center of Peking University, General Hospital of the army, Tianjin People's Hospital, Xiangya Hospital of Central South University, Chengdu first people's Hospital, Qilu Hospital of Shandong University The expert group said that the results of this trial will provide more evidence-based basis for clinical practice Chongqing kangke'er, the health messenger of diabetes patients, participated in the academic feast and displayed the image of its enterprise (http://www.chemdrug.com/company/) in the way of academic satellite meeting, academic sharing and clinical exchange Chongqing kangke'er is committed to becoming a health messenger for diabetics (http://www.chemdrug.com/article/7/), focusing on the research and development of diabetes drugs (http://www.chemdrug.com/), and health products, forming a strong diabetes product group The five major categories of oral hypoglycemic drugs covered are all in the top ten of clinical use rate With first-line drugs metformin and glimepiride, gliclazide can improve the microvascular disease of gliclazide, quickly reduce postprandial hyperglycemia of nateglinide, and quickly take glipizide orally disintegrating tablets Chongqing kangkeri is not satisfied with the existing structure of diabetes products Its scientific research team has been tracking the latest research trends of diabetes in the international forefront and has obtained clinical approval documents of several new diabetes drugs (http://www.chemdrug.com/) Chongqing kangkeri rich diabetes products have been widely praised and recognized by experts attending the meeting! Chongqing kangkeri, together with the Chinese Medical Association, aims to work with experts and front-line medical workers to protect the health of diabetic patients It is the common goal of diabetes prevention and treatment workers to let more than 100 million diabetics in China work and live carefree and make every family full of laughter Chongqing Kangke er's unremitting efforts, only for the moment smile of sugar friends!